Type of securities : Common share | Effective Date : 25/09/2020 | Close Selling Date : 30/09/2020
ประเภทหลักทรัพย์ : หุ้นสามัญ | วันที่มีผลใช้บังคับ : 25/09/2563 | วันที่ปิดการขาย : 30/09/2563
17 3.3.2 !* '#$$" * 19 7 20 '). 21 3 *"!+ ,"#$/ C.%(','# .KLM$"N .' !! ')'#+")'".)%O* (P.%NO.'* +M$ "P% .'..O* 'Q)Q R" +*')'#+"O#" +M$.%#$ !. '$".'',' !KO*!LC#+M$SK?$" P. ')'#+".)%#SO#" (C#T
shared her perspective and vision for leading the SEC organization after recently assuming office. “I have taken on a new role in a familiar organization and working environment, with the primary goal of
shared her perspective and vision for leading the SEC organization after recently assuming office. “I have taken on a new role in a familiar organization and working environment, with the primary goal of
collaterals in margin accounts have experienced price volatility and declines due to various factors. When stock prices drop, the value of the collaterals is subsequently affected, leading brokers to forcibly
Investor Alert สำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ Printed on 01 April 2025 10:22 Investor Alert Investor Alert ( 5917 record(s) found) Name Type of action Disclosure Date Link Facebook page "Amz-Dreamy Cafe Thai COffee Daily" impersonates "PTT Oil and Retail Business Plc." Unlicensed securities and derivatives business 27/03/2025 Detail Facebook page "Amz-Dreamy Cafe Thai COffee Daily" impersonates "PTT Oil and Retail Business Plc." Website : N/A Facebook : https://www.facebook.c...
2025-01-09 2020 9 Security IPO SCM Sep 8 2020 12:00AM 0 0 2025-01-09 2020 9 Security IPO SK Oct 8 2020 12:00AM 115348120 92.278496 2025-01-09 2020 10 Security IPO DHOUSE Oct 26 2020 12:00AM 217200000
2025-01-09 2020 9 Security IPO SCM Sep 8 2020 12:00AM 0 0 2025-01-09 2020 9 Security IPO SK Oct 8 2020 12:00AM 115348120 92.278496 2025-01-09 2020 10 Security IPO DHOUSE Oct 26 2020 12:00AM 217200000
maintained its leading position, and herbal-variant Som In-Sum (+64.4% YoY). Functional drinks showed impressive growth, which was driven by the success of both C-Vitt and Peptein, where we have maintained our